Swine vaccine targeting pathogenic PCV2b strains
This technology is a vaccine for Porcine Circovirus Type 2 (PCV2), a widespread and costly virus in the global pork industry. Researchers created a hybrid virus by taking the harmless shell of one virus (PCV1) and inserting the protective surface proteins from the harmful version (PCV2b). This 'chimeric' approach creates a live but weakened vaccine that triggers a strong immune response without making the pigs sick. It is specifically designed to target the most common modern strain of the virus, providing broader protection than older vaccines.
What you could build
A live-attenuated or inactivated injectable vaccine for swine, sold to large-scale commercial pork producers and veterinary pharmaceutical distributors.
Who in Virginia should care
Virginia's major swine production sector, including giants like Smithfield Foods, would benefit from improved herd health outcomes and reduced mortality rates.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Xiang-Jin MENG, Nathan M. Beach, Sheela Ramamoorthy
- Granted
- April 4, 2017
- Status
- Granted patent
- Patent number
- 9610344
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.